Zealand Pharma licenses Generate Biomedicines AI platform for metabolic proteins
The deal pairs Zealand's metabolic-disease development work with Generate's machine-learning protein design in a collaboration and license agreement.
TR
By Tom Reyes · Markets Editor
Oct 13 16:30 ETSource: Yahoo Finance
The wire
- 01Zealand Pharma and Generate Biomedicines announced a collaboration and license agreement to develop AI-engineered protein therapeutics for metabolic diseases.
- 02Zealand is a long-standing peptide developer in obesity and metabolic disease, and the tie-up signals continued movement from classical peptide chemistry toward computationally designed biologics.
- 03Financial terms, targets and timelines were not detailed in the announcement, and no candidate has been named.
From the source
Read at finance.yahoo.comZealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
